Abbott Laboratories vs. Lexicon Pharmaceuticals, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| ABT | LXRX | |
|---|---|---|
| Market Cap | $187.95 billion | $1.07 billion |
| Revenue (TTM) | — | $41.47 million |
| Net Income (TTM) | — | $-61,117,000 |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | LXRX | |
|---|---|---|
| Price / Book | — | 6.12 |
| Price / Sales | — | 25.75 |
ABT and LXRX split the valuation factors evenly.
Profitability
| ABT | LXRX | |
|---|---|---|
| Net Margin | — | -147.38% |
| Return on Equity | — | -35.02% |
ABT and LXRX split the profitability factors evenly.
Dividend
| ABT | LXRX | |
|---|---|---|
| Dividend Yield | 2.32% | — |
ABT and LXRX split the dividend factors evenly.
Risk & Sentiment
| ABT | LXRX | |
|---|---|---|
| Short Interest | 0.57% | 2.42% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, LXRX overview, LXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.